BV has demonstrated significant efficacy in treating relapse/refractory CD30-positive malignancies, particularly classical Hodgkin lymphoma (cHL) and the NHL subtypes [2], systemic anaplastic large cell lymphoma (sALCL), and cutaneous T-cell lymphoma (CTCL) [3,4,5,6,7]. Here, TNFRSF8 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.